Immunomedics, Inc. (NASDAQ:IMMU) currently has a “Sell” signals on Composite indicators by TrendSpotter. While the Short-Term Technical Indicators for the stock on 7-Day Average Directional Indicator shows “Sell” signal. 10 – 8 Day Moving Average Hilo Channel shows “Hold” signal. While 20-Day Moving Average VS Current Price shows “Sell” Signal.
Immunomedics, Inc. (NASDAQ:IMMU) gained 4.3 Percent and closed its previous trading session at $20.61. The stock traded with the average Volume of 1.57 Million at the end of last session.
Immunomedics, Inc. (NASDAQ:IMMU) has the Market Capitalization of 3.93 Billion. The Stock has its 52-week High of $27.33 and 52-Week Low of $ 8.68 and it touched its 52-week high on 07/18/18 and 52-Week Low on 12/05/17
The company reported its last earnings Actual EPS of $-0.68/share. While, the analyst predicted that the company could provide an EPS of $-0.22/share. Hence the difference between Predicted EPS and Actual EPS reported is $-0.46/share which shows an Earnings Surprise of -209.1 Percent.
The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -2.78% where SMA50 and SMA200 are -9.16% and 3.05% respectively.
The company shows its Return on Assets (ROA) value of -80.9%. The Return on Equity (ROE) value stands at -258.5%. While it’s Return on Investment (ROI) value is -33.6%.
Immunomedics, Inc. (NASDAQ:IMMU) currently has a Weekly Volatility of 6.65% percent while its Monthly Volatility is at 4.84% percent. While talking about Performance of the Stock, Immunomedics, Inc. currently has a Weekly performance of 1.38%, monthly performance percentage is -14.52 percent, Quarterly performance is -19.43 percent, 6 months performance shows a percent value of 26.91% and Yearly Performance is 75.11 percent.
Immunomedics Inc. is a New Jersey-based biopharmaceutical company focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. They have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics or toxins, in each case to create highly targeted agents. Using these technologies, the company have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. They have recently licensed its lead product candidate, epratuzumab, to UCB, S.A. for the treatment of all autoimmune disease indications worldwide.